A new clinical trial from Yale University evaluates the Portable Rehabilitation Interface PoRI for hand rehabilitation after stroke. The study status is not yet recruiting, and the sponsor is Yale University. The device PoRI is described as a portable platform intended to support rehabilitation of hand function in stroke survivors. The information below summarizes the available details from ClinicalTrials.gov and related sponsor information.
In this article
- What is PoRI and what is its intended use?
- Who leads the study and what is its current status?
- What are the regulatory considerations for PoRI?
- What should clinicians and researchers watch for next?
What is PoRI and what is its intended use?
PoRI stands for Portable Rehabilitation Interface. The device is described in the source text as a portable rehabilitation interface for post stroke hand rehabilitation. The sponsor is Yale University. The current record indicates not yet recruiting. The description does not detail technical specifications or mechanisms in the provided text. The intended population is post stroke patients with hand impairment.
What does the available text say about device functions?
The source text does not provide device functions or technical details. It identifies PoRI as a portable rehabilitation interface and lists Post Stroke Hand Rehabilitation as a condition. The aim appears to be rehabilitation support for hand function in this population. No efficacy claims are stated in the source.
What is the trial status and who sponsors it?
The ClinicalTrials.gov record for NCT07407023 lists conditions Post Stroke and Post Stroke Hand Rehabilitation. The sponsor is Yale University. The study status is Not yet recruiting. The Interventions field lists a Device called Portable Rehabilitation Interface PoRI.
What does not recruiting imply?
Not yet recruiting indicates that enrollment has not started. No patient results are available yet. The record describes planning activity rather than completed enrollment.
What are the regulatory considerations for PoRI?
The description of PoRI in the source text identifies an intended use in rehabilitation. For regulatory purposes the intended use and safety data will be defined in future submissions. The MDR style requires clear statements of intended purpose, performance and safety by the manufacturer; current text identifies the device name, sponsor and target condition but does not provide performance data. Readers should note that regulatory claims will depend on future data from studies and filings. The provided ClinicalTrials.gov link serves as an external reference to the trial record.
What additional information should be sought?
Readers should monitor ClinicalTrials.gov for updates on enrollment and results. Investigators may publish protocols or updates on the PoRI device and its performance in post stroke hand rehabilitation.
What should clinicians and researchers watch for next?
As this is not yet recruiting, no patient data are available yet. The trial status signals an early stage of PoRI evaluation. The sponsor and site information indicate ongoing oversight by Yale University. Updates may include enrollment start date protocol details and safety assessments. Clinicians may consider PoRI as a potential option once results are published and regulatory filings are completed.
FAQ
- 1. What is PoRI? The Portable Rehabilitation Interface described in the source text is a device intended for hand rehabilitation after stroke.
- 2. What is the purpose of the PoRI trial? The trial aims to evaluate a portable device for hand rehabilitation in post stroke patients, with enrollment not yet started.
- 3. Who is sponsoring this study? Yale University is listed as the sponsor.
- 4. Where can I find more information? The ClinicalTrials.gov page linked in the source text provides the trial record.
Conclusion
The PoRI trial is in early stages with no enrollment yet. The device is described as a portable rehabilitation interface for post stroke hand rehabilitation. Regulatory considerations will depend on data from future studies and submissions. Stakeholders should monitor the ClinicalTrials.gov record for updates and any regulatory filings.